by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Email this page to a friend
Search this issue
Index - jump to page or section
Archive - view past issues
Australian Journal of Pharmacy : October 2006
company news company news Entrepreneurial recognition for Ego MD A LAN Oppenheim, the managing director of Ego Pharmaceuticals, was announced winner of the Retail, Consumer and Industrial Products Cat- egory for the Southern Region of the Entrepreneur of the Year Awards. The Entrepreneur of the Year cele- brates entrepreneurs who build and lead successful businesses, recognising them through regional, national and global award programs across 40 nations. ‘I see this award as recognising the whole of Ego Pharmaceuticals, which is a team of entrepreneurs working closely with pharmacists to help speed the growth of pharmacy in 24 nations,’ said Mr Oppenheim (pictured far right). Rationalisation of Big Pharma gathers pace G ERMAN generics giant Merck KgaA, owner of Alphapharm, has announced its intention to buy biotech company, the Serono Group, in a deal valuing the company at US$13.3bn. It agreed to purchase from the Bertarelli family their 64.5 per cent majority stakeholding in the company and said it intended buying the rest of the company from other shareholders. Serono markets psoriasis treatment Raptiva (eflizumab) and MS medicine Rebif (interferon 1-b). In other acquisition news, speculation is growing that more suitors are lining up to put in a bid for Mayne Pharma. US specialty pharmaceuticals company Hos- pira offered $2.6bn for the company in a deal accepted by the Mayne Pharma board. Yet analysts are expecting other bidders in a rapidly rationalising market. Another sale announced recently was the pharmaceutical business of the Altana Group, Altana Pharma, to Danish com- pany Nycomed for $7.6bn. The deal is expected to be finalised by year’s end. ¦ ‘I would like to thank pharmacists and their staff—every one of them—for their strong ongoing support of Ego.’ ‘The government’s changes to the PBS will significantly reduce the profit of every Australian pharmacy. That just increases the urgency for pharmacy to build their OTC business faster. ‘The breadth and strength of the Ego brands are perfectly placed for pharmacy to use them to restore profits, through faster sales growth. Ego is core to OTC pharmacy in terms of business, offering professional advice and helping people,’ said Mr Oppenheim. Ego is investing $13m over two years to significantly increase production capacity at its own world-class facility in Mel- bourne. Its export sales grew 41 per cent in 2005/6, with products now available in 24 countries. ¦ EADING pharmaceutical and com- plementary medicines manufactur- ers were recognised for excellence at the industry awards at the Australian Self- Medication Industry Conference in Syd- ney last month. The Parliamentary Secretary to the Minister for Health and Ageing, Christo- pher Pyne announced the awards at the ASMI Annual Awards Banquet at Sydney Olympic Park. Now in its fourth year, the awards hon- our achievement in product introductions and promotional programs in both the over-the-counter (OTC) and complemen- tary medicines sectors. The judging of the awards takes into account both commercial considerations as well as application of Quality Use of Medicines principles. ‘These companies can be proud of their achievement in a growing and highly competitive market,’ Ms Seifert said. Best new product: Codral and Sudafed PE by Pfizer Consumer Healthcare The judging panel said the winning entry was developed following a realisation that there was a problem for consumers and 64 ? THE AUSTRALIAN JOURNAL OF PHARMACY VOL.87 OCTOBER 2006 Pfizer scoops ASMI marketing awards L Best promotion of an existing product— OTC category: Joint winners—Panadol and Children’s Panadol by GlaxoSmithKline, and Diflucan One by Pfizer Consumer Healthcare The panel noted that Panadol demon- strated how to use professional endorse- ment in a responsible manner. It also included QUM references in its promo- tional material. Judges commented that Diflucan One provided good pharmacist support mate- rials together with consumer-oriented information. Best promotion of an existing product— Complementary category: Blackmores Joint Formula by Blackmores. The judges said that the Blackmores Joint Formula operated in a highly contested category and used healthcare professional endorsement in a constructive manner. ¦ pharmacists. The company took on an industry leadership role by undertaking good innovative R&D. The marketing campaign was thorough and complete, and the product achieved excellent mar- ket share.